These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. [The pulmonary surfactant system: physiology, pathologies associated with its alteration and exogenous administration as therapeutic and diagnostic agent]. Calmanovici G; Boccio J; Lysionek A; Salgueiro M; Caro R; Hager A; de Paoli T; Zubillaga M Acta Physiol Pharmacol Ther Latinoam; 1998; 48(4):175-90. PubMed ID: 9914807 [TBL] [Abstract][Full Text] [Related]
31. [Acute respiratory distress syndrome--effective therapeutic methods, at last?]. Skeie B Tidsskr Nor Laegeforen; 1996 Apr; 116(10):1208-9. PubMed ID: 8658389 [No Abstract] [Full Text] [Related]
32. [Bases of the replacement surfactant therapy for bronchopulmonary diseases]. Zagorul'ko AK; Kliaritskaia IL Lik Sprava; 2004; (5-6):79-86. PubMed ID: 15605831 [TBL] [Abstract][Full Text] [Related]
33. Does surfactant therapy prolong dying? Age at in-hospital death of extremely premature babies. Coulter DM; Jung AL J Perinatol; 1996; 16(3 Pt 1):166-70; quiz 171-2. PubMed ID: 8817423 [TBL] [Abstract][Full Text] [Related]
34. Therapeutic use of nitric oxide in critical settings. Braschi A; Iannuzzi M; Belliato M; Iotti GA Monaldi Arch Chest Dis; 2001 Apr; 56(2):177-9. PubMed ID: 11499314 [No Abstract] [Full Text] [Related]
35. Artificial surfactant to prevent and treat neonatal respiratory distress syndrome. Enhorning G Pediatrics; 1980 Nov; 66(5):799-800. PubMed ID: 7432889 [No Abstract] [Full Text] [Related]
36. Inhaled corticosteroids for respiratory distress? de Nucci G; Moncada S Lancet; 1985 Nov; 2(8463):1061. PubMed ID: 2865531 [No Abstract] [Full Text] [Related]
37. Current perspectives in pulmonary surfactant--inhibition, enhancement and evaluation. Zuo YY; Veldhuizen RA; Neumann AW; Petersen NO; Possmayer F Biochim Biophys Acta; 2008 Oct; 1778(10):1947-77. PubMed ID: 18433715 [TBL] [Abstract][Full Text] [Related]
38. [Factors affecting clinical response to surfactant therapy in neonates with severe respiratory distress syndrome]. Fujiwara T; Chida S; Konishi M Nihon Kyobu Shikkan Gakkai Zasshi; 1991 Jan; 29(1):29-34. PubMed ID: 2041254 [TBL] [Abstract][Full Text] [Related]
39. A risk-benefit assessment of natural and synthetic exogenous surfactants in the management of neonatal respiratory distress syndrome. Walti H; Monset-Couchard M Drug Saf; 1998 May; 18(5):321-37. PubMed ID: 9589844 [TBL] [Abstract][Full Text] [Related]
40. Untapped therapeutic potential of surfactant proteins: is there a case for recombinant SP-D supplementation in neonatal lung disease? Clark HW Neonatology; 2010 Jun; 97(4):380-7. PubMed ID: 20551708 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]